Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

By P. Halkes, J. van Gijn, L. Kappelle, P. Koudstaal, Ale Algra. The Lancet, 2006

963 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/90d0217640254105ba3cf65c223bf502aa33fac9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Brainin
2. G. Howard
3. D. Lackland
4. P. Ringleb
5. Eric E. Smith
6. Álvaro Cervara
7. G. Ford
8. Mary G. George

Citations in the corpus

• Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. (2008, background): “Table 7: Relative risk reduction (RRR), absolute risk reduction (ARR) and number needed to treat (NNT) to avoid one major vascular event per year in patients with antithrombotic therapy (modified from [318, 321, 582])”
• Factors Influencing the Decline in Stroke Mortality (2013, background): “10),(311) with neither trial finding that aspirin and dipyridamole reduced the risk of vascular or all-cause death compared with aspirin.(310,311) In a subsequent randomized, controlled trial, aspirin and sustained-release dipyridamole were not superior to clopidogrel for secondary prevention of rec”